#NAME?
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
AbbVie extends oncology reach via in-situ CAR-T pact worth $1.4B
AbbVie penned two deals with Umoja Biopharma for its in vivo CAR-T cell therapy programs, the companies announced Thursday.
IASO BIO Announces New Development Partnership with Umoja Biopharma
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T...
Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec„¢ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell...